U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday.

Shares of Olema Pharmaceuticals Inc (NASDAQ:OLMA) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO 2025.

Olema Pharmaceuticals shares dipped 18.3% to $7.64 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Concord Medical Services Hldgs Ltd (NYSE:CCM) fell 24.4% to $4.15 in pre-market trading after dipping 6% on Friday.
• Addex Therapeutics Ltd – ADR (NASDAQ:ADXN) dipped 15.6% to $9.23 in pre-market trading after gaining 28% on Friday.
• Exelixis Inc (NASDAQ:EXEL) fell 8.3% to $36.00 after the company announced detailed results from Phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer presented at ESMO 2025 and published in The Lancet.
• Cellectis SA (NASDAQ:CLLS) fell 7.3% to $3.69 in pre-market trading.
• Alumis Inc (NASDAQ:ALMS) declined 6.7% to $4.19 in pre-market trading.
• Nanobiotix SA – ADR (NASDAQ:NBTX) fell 6.3% to $23.98 in pre-market trading after declining 4% on Friday.
• Genmab A/S – ADR (NASDAQ:GMAB) declined 4.1% to $31.81 in pre-market trading. Genmab’s Rinatabart Sesutecan achieved 50% objective response rate and two complete responses in advanced endometrial cancer.
• Taysha Gene Therapies Inc (NASDAQ:TSHA) fell 4% to $4.53 in pre-market trading.

Now Read This:

• ‘No Need To Sell’ Martin Marietta Materials, Cramer Says: ‘It’s Just A Great Long-Term Hold’

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.